Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
08/29/2022 - 04:05 PM
AUSTIN, Texas Aug. 29, 2022 Germany August 30 – September 2 . The presentations include perspectives on dietary management of Homocystinuria, which will be given as both an oral and poster presentation, as well as additional safety and efficacy data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency.
Homocystinuria Presentations:
Title: Dietary management of homocystinuria (HCU) caused by cystathionine beta-synthase (CBS) deficiency: Perspectives from a global cohort of metabolic dietitiansAugust 31 , 11:15 – 11:30 am CEST August 31 , 6:45 – 8:15 pm CEST Washington, DC
Pegzilarginase Presentations:
Oral Presentation
Title: Pegzilarginase efficacy in Arginase 1 Deficiency: Results of the PEACE pivotal phase 3 trialSeptember 1 , 3:15 – 3:30 pm CESTEmory University School of Medicine , Atlanta, Georgia
Poster Presentation
Title: Safety and tolerability of pegzilarginase for Arginase 1 Deficiency in the PEACE pivotal phase 3 clinical trialAugust 31 , 6:45 – 8:15 pm CEST Emory University School of Medicine , Atlanta, Georgia
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea is investigating AGLE-177 in an ongoing Phase 1/2 clinical trial for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea's other clinical program, pegzilarginase, achieved the primary endpoint of arginine reduction in the PEACE Phase 3 clinical trial and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com .
https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-presentations-at-the-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-annual-symposium-2022-301614007.html
SOURCE Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics Inc
AGLE Rankings
#4882 Ranked by Stock Gains
AGLE Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About AGLE
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
